Phase 1 first-in-human study of anti-ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results

被引：0
|
作者：
Gutierrez, Martin
Spreafico, Anna
Wang, Ding
Golan, Talia
Renouf, Daniel
Voskoboynik, Mark
Chatterjee, Manash Shankar
Kapadia, Kishan J.
Liu, Qi
Kovvali, Gopala
Suttner, Leah
Pang, Ling
Chen, Mei
Tolcher, Anthony W.
机构：
[1] Hackensack Univ Med Ctr, Hackensack, NJ USA
[2] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Merck Co Inc, Kenilworth, NJ USA
[4] Henry Ford Hosp, Detroit, MI USA
[5] Tel Aviv Univ, Sheba Med Ctr, Ramat Gan, Israel
[6] BC Cancer, Vancouver, BC, Canada
[7] Univ British Columbia, Vancouver, BC, Canada
[8] Monash Univ, Cent Clin Sch, Alfred Hlth, Melbourne, Vic, Australia
[9] Merck Co Inc, Kenilworth, NJ USA
[10] South Texas Accelerated Res Therapeut, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2505
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A first-in-human phase 1 dose-escalation and expansion study of intratumoral oncolytic reovirus (RC402) as a monotherapy or in combination with pembrolizumab in advanced solid tumors
    Voskoboynik, Mark
    Liu, Jia
    Song, Ki-Hoon
    Park, Dong-Guk
    Ryu, Min-Hee
    Chon, Hong Jae
    Kim, Chan
    CANCER RESEARCH, 2024, 84 (07)
  • [2] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Keedy, Vicki L.
    Lenz, Heinz-Josef
    Saltz, Leonard
    Whisenant, Jennifer G.
    Berlin, Jordan D.
    Camacho, Luis H.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 860 - 868
  • [3] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Vicki L. Keedy
    Heinz-Josef Lenz
    Leonard Saltz
    Jennifer G. Whisenant
    Jordan D. Berlin
    Luis H. Camacho
    Investigational New Drugs, 2018, 36 : 860 - 868
  • [4] A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors: Dose escalation study
    Taylor, Matthew H.
    Patel, Manish R.
    Powderly, John D.
    Woodard, Paul
    Chung, Luke
    Tian, Hongyu
    Hong, Xiang
    Hong, Kyu
    Valencia, Donna
    Huang, Tao
    Schebye, Xiao Min
    Liao, Charlene
    Naing, Aung
    CANCER RESEARCH, 2023, 83 (08)
  • [5] Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors
    Perets, R.
    Stemmer, S. M.
    Geva, R.
    Golan, T.
    Fakih, M.
    Cohen, J. E.
    Lieu, C.
    Jin, Z.
    Lorusso, P.
    Friedman, I.
    Hakim, M.
    Ziv, D. Haves
    Hashmueli, S.
    Mandel, I.
    Ben Moshe, T.
    Crawford, N.
    Abbadessa, G.
    Perez, R.
    Wu, M.
    Borad, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S675 - S675
  • [6] A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.
    Tolcher, Anthony W.
    Carneiro, Benedito A.
    Dowlati, Afshin
    Razak, Albiruni Ryan Abdul
    Chae, Young Kwang
    Villella, Jeannine A.
    Coppola, Sheryl
    Englert, Stefan
    Phillips, Andrew C.
    Souers, Andrew J.
    Salman, Zeena
    Penugonda, Sudhir
    Powderly, John D.
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
    Lin, C-C.
    Schneider, R.
    Gutierrez, M.
    Shen, L.
    Chung, K.
    Doroshow, D. B.
    Gao, B.
    Millward, M.
    Hsieh, C-Y.
    Xu, C.
    Cai, S. X.
    Tian, Y. E.
    Liu, L.
    Shen, C.
    Tan, Y.
    He, Y.
    Zhang, C.
    Li, L.
    Ma, M.
    Xu, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S503 - S504
  • [9] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours
    Martin-Liberal, Juan
    Hollebecque, Antoine
    Aftimos, Philippe
    Jungels, Christiane
    Martin-Romano, Patricia
    Rodon, Jordi
    Kremer, Jill Dolores
    Zhang, Wei
    Bendell, Johanna
    BRITISH JOURNAL OF CANCER, 2020, 123 (08) : 1235 - 1243
12345